SS-31 vs MOTS-c: Which Is Better for Mitochondrial Function?
SS-31 vs MOTS-c is becoming one of the more interesting comparisons in mitochondrial research. But real-world epigenetic data suggest that asking which peptide is “better” may be the wrong question.
SS-31 (elamipretide) and MOTS-c approach mitochondrial function through distinctly different biological pathways. SS-31 is associated primarily with the inner mitochondrial membrane and cardiolipin, while MOTS-c is a mitochondrial-derived peptide involved in metabolic signalling, cellular stress responses and pathways including AMPK.
That distinction matters because mitochondrial dysfunction is not one single problem.
Data collected through Epic Genetics, alongside the longitudinal results of founder Tony Pemberton, suggest that some people may show a stronger response in markers associated with mitochondrial dynamics from MOTS-c, while others may demonstrate greater changes in ATP-related markers from SS-31.
Tony's own results illustrate this particularly well.
SS-31 vs MOTS-c: two different approaches to mitochondrial health
SS-31 is a mitochondria-targeted tetrapeptide that interacts with cardiolipin, an important phospholipid concentrated within the inner mitochondrial membrane.
Cardiolipin plays a structural role in the machinery responsible for oxidative phosphorylation and ATP production. When mitochondrial membranes become dysfunctional, energy production can become less efficient and oxidative stress can increase.
SS-31 has therefore attracted considerable scientific interest as a potential means of improving mitochondrial bioenergetics.
MOTS-c works differently.
MOTS-c is a mitochondrial-derived peptide encoded within mitochondrial DNA. Rather than principally targeting mitochondrial membrane structure, research suggests that it functions as a metabolic signalling molecule and can influence pathways including AMPK.
AMPK acts as one of the cell's major energy sensors. When cellular energy availability falls, AMPK helps shift metabolism toward pathways that generate energy while suppressing some energy-consuming processes.
This creates an important distinction:
SS-31 may be particularly relevant to mitochondrial membrane and bioenergetic dysfunction, whereas MOTS-c may exert more pronounced effects on metabolic signalling and mitochondrial adaptation.
That does not mean everybody will respond in the same way.
What did the real-world epigenetic data show?
Epic Genetics previously examined changes in mitochondrial biomarkers before and after exposure to SS-31 and MOTS-c using True Health epigenetic testing.
Two markers produced a particularly interesting contrast: DRP1 and ATP5B.
DRP1 is involved in mitochondrial fission — the process through which mitochondria divide. Fission is essential and should not simply be regarded as “bad”, but excessive or poorly regulated fission can occur alongside mitochondrial stress.
ATP5B, meanwhile, relates to mitochondrial ATP synthase and therefore provides a different window into mitochondrial energy metabolism.
Across the Epic Genetics case-study cohorts, MOTS-c was associated with an average 13-point improvement in DRP1, compared with approximately seven points with SS-31.
ATP5B showed almost the opposite pattern.
SS-31 produced an average ATP5B improvement of approximately 18.5 points, compared with 9.5 points in the MOTS-c cohort.
These are observational, real-world results rather than randomized clinical-trial evidence, and they should be interpreted accordingly. Nevertheless, the contrasting pattern is interesting.
Rather than showing that one compound universally outperformed the other, the data suggest potentially different mitochondrial response profiles.
Tony Pemberton's results: the difference becomes even clearer
Tony Pemberton provides a separate longitudinal example because he has undergone repeated True Age and True Health testing alongside CGM monitoring.
During an earlier SS-31 period, Tony used SS-31 for approximately 70 days. His exposure was relatively modest compared with his current research period.
The subsequent MOTS-c period ran from 18 May until 14 August — 88 days, or approximately 12½ weeks.
His mitochondrial dynamics changed substantially.
Tony's DRP1 moved from approximately the 82nd percentile to the 50th percentile, bringing the marker almost exactly into the middle of the reference distribution.
For Tony, this was a considerably larger DRP1 movement than he had observed during his preceding SS-31 period.
ATP5B also moved in a favourable direction during the MOTS-c period, although much less dramatically. It fell by another 5 percentile points to around the 47th percentile.
This broadly resembles the pattern observed across the wider Epic Genetics case-study data:
MOTS-c appeared particularly interesting for DRP1, whereas SS-31 produced the larger average ATP5B change.
That is still correlation rather than proof of mechanism, but seeing a similar pattern across individual longitudinal data and a small real-world cohort makes the observation worth investigating further.
But Tony's glucose data told a different story
This is where the comparison becomes especially interesting.
Despite Tony's strong DRP1 response during MOTS-c, his continuous glucose monitor suggested that SS-31 may have been considerably more effective for his personal glucose control.
During his earlier SS-31 period, his CGM-derived estimated HbA1c was approximately 28 mmol/mol, based on 62 days of CGM data within a 90-day period.
During the subsequent MOTS-c period, average glucose was initially around 4.6–4.8 mmol/L.
There is an important confounder: Tony was also taking the SGLT2 inhibitor empagliflozin for part of this period.
A pharmacy shortage subsequently interrupted his normal empagliflozin supply. MOTS-c was continued for longer than originally intended while Tony monitored what happened to his glucose.
Without his normal SGLT2 treatment, average CGM glucose eventually climbed to approximately 5.1 mmol/L, with occasional postprandial excursions reaching roughly 7.5 mmol/L.
His laboratory HbA1c subsequently measured approximately 36 mmol/mol, compared with historical results closer to 30 mmol/mol.
Those numbers cannot establish that MOTS-c caused the deterioration — medication availability, diet, activity and numerous other variables influence glucose — but they suggest that MOTS-c was not sufficient to reproduce Tony's previous glucose profile.
His current SS-31 period has produced a strikingly different CGM pattern.
Average glucose has recently been approximately 4.4–4.5 mmol/L.
Again, this is an individual observation rather than a controlled experiment. But Tony appears personally to demonstrate a stronger glucose response during SS-31 exposure than during MOTS-c.
Interestingly, Epic Genetics has seen the opposite pattern in some clients, with certain individuals appearing more responsive to MOTS-c on CGM.
That variability may be one of the most important findings of all.
Research Disclaimer
These case studies are observational and are presented for educational and research purposes only. They do not demonstrate that SS-31 or MOTS-c caused the changes described and should not be interpreted as medical advice or as evidence of efficacy or safety. The findings represent real-world observations, and individual responses may vary considerably.
Tony Pemberton and 50% of the participants featured in these case studies sourced their UK research peptides through Elvian Labs, selected due to the availability of recent independent product testing alongside periodic sterility testing.
Why glucose exposure matters to mitochondrial health
Glucose control is not separate from mitochondrial health. The two systems are intimately connected.
Mitochondria are central to cellular energy metabolism, while chronic metabolic overload can increase mitochondrial oxidative stress and alter mitochondrial dynamics.
Likewise, mitochondrial dysfunction can impair metabolic flexibility.
This creates a two-way relationship between mitochondrial health and metabolic health.
Periods of caloric excess, insulin resistance, repeated glucose excursions, oxidative stress and environmental stressors can all influence the cellular environment in which mitochondrial fusion and fission occur.
However, mitochondrial fission itself should not be treated as pathological. Cells require a balance between fusion and fission to maintain mitochondrial quality.
This is why DRP1 is potentially more informative when examined longitudinally alongside other biomarkers rather than interpreted as a standalone “higher is always worse” measurement.
What happened to Tony's biological heart age?
Another notable change occurred during Tony's approximately 12½-week MOTS-c period.
His True Health heart age improved by 6.2 years.
Cardiovascular ageing had historically been one of Tony's weaker biological systems, making the magnitude of the change particularly interesting.
It cannot be attributed solely to MOTS-c: biological-age measurements respond to multiple inputs, and Tony was simultaneously managing exercise, diet, glucose and other interventions.
Nevertheless, this is exactly why repeated True Health and True Age testing can be useful in real-world longevity research.
Rather than relying purely on how somebody feels, epigenetic testing allows changes across biological systems to be followed longitudinally.
Epic Genetics provides access to True Diagnostic testing in the UK, including True Age and True Health, and uses repeated testing to examine whether interventions correspond with measurable biological changes over time.
Do you need more AMPK signalling or better mitochondrial membrane function?
This may eventually prove more useful than asking simply:
“Is SS-31 better than MOTS-c?”
Consider two hypothetical individuals.
One already performs considerable fasted exercise, maintains high physical activity and uses other interventions associated with AMPK activation. Adding another intervention acting partly through metabolic stress signalling might produce a different response from somebody who is sedentary and metabolically unhealthy.
Another person might have relatively good metabolic signalling but poorer mitochondrial membrane function or bioenergetics.
Their response to SS-31 could potentially look quite different.
Tony may represent something closer to the first situation. He performs regular fasted cardiovascular exercise and already employs several metabolic interventions.
His results suggest that additional MOTS-c exposure was nevertheless associated with a substantial improvement in DRP1.
Yet his glucose response appears stronger during SS-31 exposure.
In other words, different aspects of his mitochondrial biology appear to respond differently to the two compounds.
Can SS-31 be used for longer than MOTS-c?
Another potential difference concerns duration of exposure.
SS-31 does not operate by simply agonising a conventional cell-surface receptor. Its interaction with mitochondrial membranes and cardiolipin has led to clinical investigation over substantially longer periods than the short research cycles commonly discussed within the peptide community.
Longer-duration elamipretide studies have extended for many months in clinical research.
That does not prove that tolerance cannot occur, nor does it establish an optimal duration for SS-31.
MOTS-c is different again. Anecdotally, some peptide researchers report diminishing subjective or metabolic responses during prolonged exposure and therefore favour shorter periods of research.
There is not yet sufficient human clinical evidence to establish an optimal MOTS-c cycling strategy, so anecdotal reports should not be mistaken for clinical guidance.
Tony's approach going forward is therefore based on his own biomarker response: he intends to investigate SS-31 more regularly while retaining shorter MOTS-c research periods because of the pronounced DRP1 response observed during MOTS-c.
SS-31 vs MOTS-c: which is better?
At present, there isn't enough evidence to declare a universal winner.
The Epic Genetics data instead raise a more interesting possibility.
MOTS-c produced the larger average DRP1 improvement.
SS-31 produced the larger average ATP5B improvement.
Tony's personal data broadly followed the DRP1 pattern, with DRP1 moving from approximately the 82nd to the 50th percentile during his MOTS-c period.
Yet his glucose response appears to favour SS-31, with current CGM averages around 4.4–4.5 mmol/L compared with approximately 5.1 mmol/L during the later MOTS-c period without his normal SGLT2 medication.
That is why the future of mitochondrial optimisation may not be about finding the single “best mitochondrial peptide”.
It may be about identifying which component of mitochondrial biology needs attention in the individual standing in front of you.
For people researching SS-31 vs MOTS-c, mitochondrial peptides, UK peptides or where to buy peptides UK, purity testing is only one part of that equation. Objective measurement before and after an intervention is arguably far more informative than assuming that a compound will produce the same response in everyone.
Real-world CGM data, conventional metabolic blood markers and longitudinal epigenetic testing through platforms such as True Health and True Age can provide different pieces of that picture.
The early Epic Genetics results suggest something important:
Mitochondrial optimisation may need to be personalised — because two interventions can improve mitochondrial function while producing very different effects on DRP1, ATP5B, glucose metabolism and biological ageing in the same person.
Comments